SK Biopharmaceuticals Statistics

Total Valuation

SK Biopharmaceuticals has a market cap or net worth of KRW 8.00 trillion. The enterprise value is 7.93 trillion.

Market Cap	8.00T
Enterprise Value	7.93T

Important Dates

The next estimated earnings date is Monday, January 27, 2025.

Earnings Date	Jan 27, 2025
Ex-Dividend Date	n/a

Share Statistics

SK Biopharmaceuticals has 78.31 million shares outstanding.

Current Share Class	n/a
Shares Outstanding	78.31M
Shares Change (YoY)	n/a
Shares Change (QoQ)	n/a
Owned by Insiders (%)	0.02%
Owned by Institutions (%)	12.77%
Float	28.06M

Valuation Ratios

The trailing PE ratio is 139.34 and the forward PE ratio is 69.02.

PE Ratio	139.34
Forward PE	69.02
PS Ratio	15.64
PB Ratio	23.66
P/TBV Ratio	24.61
P/FCF Ratio	427.48
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 130.39, with an EV/FCF ratio of 424.12.

EV / Earnings	138.25
EV / Sales	15.51
EV / EBITDA	130.39
EV / EBIT	182.87
EV / FCF	424.12

Financial Position

The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.48.

Current Ratio	1.63
Quick Ratio	1.20
Debt / Equity	0.48
Debt / EBITDA	2.01
Debt / FCF	9.43
Interest Coverage	6.76

Financial Efficiency

Return on equity (ROE) is 14.32% and return on invested capital (ROIC) is 8.42%.

Return on Equity (ROE)	14.32%
Return on Assets (ROA)	5.77%
Return on Capital (ROIC)	8.42%
Revenue Per Employee	2.12B
Profits Per Employee	238.10M
Employee Count	241
Asset Turnover	0.67
Inventory Turnover	0.46

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +13.72% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+13.72%
50-Day Moving Average	109,666.00
200-Day Moving Average	95,850.00
Relative Strength Index (RSI)	46.31
Average Volume (20 Days)	276,315

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, SK Biopharmaceuticals had revenue of KRW 511.33 billion and earned 57.38 billion in profits. Earnings per share was 732.73.

Revenue	511.33B
Gross Profit	460.13B
Operating Income	70.47B
Pretax Income	44.57B
Net Income	57.38B
EBITDA	87.93B
EBIT	70.47B
Earnings Per Share (EPS)	732.73

Full Income Statement

Balance Sheet

The company has 267.54 billion in cash and 176.32 billion in debt, giving a net cash position of 91.22 billion or 1,164.75 per share.

Cash & Cash Equivalents	267.54B
Total Debt	176.32B
Net Cash	91.22B
Net Cash Per Share	1,164.75
Equity (Book Value)	366.26B
Book Value Per Share	4,314.86
Working Capital	213.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 19.74 billion and capital expenditures -1.03 billion, giving a free cash flow of 18.70 billion.

Operating Cash Flow	19.74B
Capital Expenditures	-1.03B
Free Cash Flow	18.70B
FCF Per Share	238.84

Full Cash Flow Statement

Margins

Gross margin is 89.99%, with operating and profit margins of 13.78% and 11.22%.

Gross Margin	89.99%
Operating Margin	13.78%
Pretax Margin	8.72%
Profit Margin	11.22%
EBITDA Margin	17.20%
EBIT Margin	13.78%
FCF Margin	3.66%

Dividends & Yields

SK Biopharmaceuticals does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	n/a
Shareholder Yield	n/a
Earnings Yield	0.72%
FCF Yield	0.23%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

SK Biopharmaceuticals has an Altman Z-Score of 10.1.

Altman Z-Score	10.1
Piotroski F-Score	n/a